Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism GJA1 inhibitors(Gap junction alpha-1 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H19ClFNO4 |
InChIKeyXLIIRNOPGJTBJD-ROUUACIJSA-N |
CAS Registry175013-84-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | Phase 3 | - | - | |
Migraine Without Aura | Phase 2 | DK | 30 Apr 2006 | |
Migraine Without Aura | Phase 2 | HU | 30 Apr 2006 | |
Migraine Without Aura | Phase 1 | ZA | 30 Apr 2006 | |
Migraine With Aura | Preclinical | DK | 30 Apr 2006 | |
Migraine With Aura | Preclinical | ZA | 30 Apr 2006 | |
Migraine With Aura | Preclinical | GB | 30 Apr 2006 | |
Migraine With Aura | Preclinical | HU | 30 Apr 2006 | |
Migraine Without Aura | Discovery | GB | 30 Apr 2006 |
Phase 2 | 39 | (gcoytcteac) = Tonabersat was well tolerated but overall had more side-effects than placebo hgxnbrypmz (zclwkfpmco ) | Positive | 01 Aug 2009 | |||
Placebo | |||||||
Phase 2 | 124 | (cyhulvxvkq) = rmlyfjbbtj lraygbkmek (tgmahnpsjd ) | - | 01 Jul 2009 | |||
Placebo | (cyhulvxvkq) = blrrunyqed lraygbkmek (tgmahnpsjd ) |